| Literature DB >> 27200009 |
Md Mahfuzur R Shah1, Yuanmei Liang1, Jay J Cheng2, Maurycy Daroch1.
Abstract
Many species of microalgae have been used as source of nutrient rich food, feed, and health promoting compounds. Among the commercially important microalgae, Haematococcus pluvialis is the richest source of natural astaxanthin which is considered as "super anti-oxidant." Natural astaxanthin produced by H. pluvialis has significantly greater antioxidant capacity than the synthetic one. Astaxanthin has important applications in the nutraceuticals, cosmetics, food, and aquaculture industries. It is now evident that, astaxanthin can significantly reduce free radicals and oxidative stress and help human body maintain a healthy state. With extraordinary potency and increase in demand, astaxanthin is one of the high-value microalgal products of the future.This comprehensive review summarizes the most important aspects of the biology, biochemical composition, biosynthesis, and astaxanthin accumulation in the cells of H. pluvialis and its wide range of applications for humans and animals. In this paper, important and recent developments ranging from cultivation, harvest and postharvest bio-processing technologies to metabolic control and genetic engineering are reviewed in detail, focusing on biomass and astaxanthin production from this biotechnologically important microalga. Simultaneously, critical bottlenecks and major challenges in commercial scale production; current and prospective global market of H. pluvialis derived astaxanthin are also presented in a critical manner. A new biorefinery concept for H. pluvialis has been also suggested to guide toward economically sustainable approach for microalgae cultivation and processing. This report could serve as a useful guide to present current status of knowledge in the field and highlight key areas for future development of H. pluvialis astaxanthin technology and its large scale commercial implementation.Entities:
Keywords: Haematoccoccus pluvialis; algae cultivation and processing; astaxanthin; biorefinery; nutraceuticals
Year: 2016 PMID: 27200009 PMCID: PMC4848535 DOI: 10.3389/fpls.2016.00531
Source DB: PubMed Journal: Front Plant Sci ISSN: 1664-462X Impact factor: 5.753
Figure 1Light microscopic images of Green vegetative motile cell; (B) Green vegetative palmella cell; (C) Astaxanthin accumulating palmella cell in transition to aplanospore; (D) Astaxanthin accumulated aplanospore cell. Scale bar: 10 μm.
Figure 2Life cycle of Fluorescence microscopy images, showing the 1- to 32-cell stages, and the flagellated stage. DIC, differential interference contrast image; SYBR, SYBR Green I-stained cells (green); CHL, chlorophyll autofluorescence (red); and Overlay, overlaid images of SYBR and CHL. (B) Illustration of life cycle of H. pluvialis. Refresh, when old cultures are transplanted into fresh medium, coccoid cells undergo cell division to form flagellated cells within the mother cell wall. Germination, Flagellated cells settle and become coccoid cells. Continuous and/or strong light accelerate the accumulation of astaxanthin during encystment (red arrows). Figure reproduced from Wayama et al. (2013) distributed under the terms of the Creative Commons Attribution License.
Figure 3Gametogenesis in . (A) C, cyst; G, gametocyst; S, a sporocyst; (B) vegetative zoospore, F, flagella (indicated by arrow); (C): gametocyst before releasing gametes; (D): release of gametes from gametocyst. Reproduced with permission from Triki et al., 1997, Phycologia, Allen Press Publishing Services. Copyright (1997) Allen Press Publishing Services.
Figure 4Transmission electron micrographs of green vegetative cells of General ultrastructure. The cell wall is surrounded by extracellular matrix (arrowheads). Arrows indicate astaxanthin granules. (B) Chloroplast and pyrenoid. C, chloroplast; CW, cell wall; N, nucleus; P, pyrenoid. Scale bars in (A,B): 5 and 1 μm, respectively. Figure reproduced from Wayama et al. (2013) distributed under the terms of the Creative Commons Attribution License.
Figure 5Transmission electron micrograph of intermediate . C, chloroplast; CW, cell wall; N, nucleus; OD; oil droplet; P, pyrenoid; SC, starch capsule; SG, starch grain. Scale bar: 5 μm. Figure reproduced from Wayama et al. (2013) distributed under the terms of the Creative Commons Attribution License.
Figure 6Transmission electron micrographs of General ultrastructure of cyst cells, showing small granules that contain astaxanthin. (B) General ultrastructure of a cyst cell, showing astaxanthin accumulation in oil droplets. (C) General ultrastructure of a cyst cell, showing large oil droplets. Chloroplasts localize in the interspace between oil droplets (arrows). (D) Some oil droplets are fused. C, chloroplast; N, nucleus; OD, oil droplet. Scale bars in (A–D): 5 μm. Figure reproduced from Wayama et al. (2013) distributed under the terms of the Creative Commons Attribution License.
Typical composition of .
| Proteins | 29–45 | 17–25 |
| Lipids (% of total) | 20–25 | 32–37 |
| Neutral lipids | 59 | 51.9–53.5 |
| Phospholipids | 23.7 | 20.6–21.1 |
| Glycolipids | 11.5 | 25.7–26.5 |
| Carbohydrates | 15–17 | 36–40 |
| Carotenoids (% of total) | 0.5 | 2–5 |
| Neoxanthin | 8.3 | n.d |
| Violaxanthin | 12.5 | n.d |
| β-carotene | 16.7 | 1.0 |
| Lutein | 56.3 | 0.5 |
| Zeaxanthin | 6.3 | n.d |
| Astaxanthin (including esters) | n.d | 81.2 |
| Adonixanthin | n.d | 0.4 |
| Adonirubin | n.d | 0.6 |
| Canthaxanthin | n.d | 5.1 |
| Echinenone | n.d | 0.2 |
| Chlorophylls | 1.5–2 | 0 |
Adapted from Grewe and Griehl (2012). n.d., no data.
Comparison of fatty acid composition (%) of two different .
| C12:0 lauric | N/A | 0.1 |
| C14:0 myristic | 0.1 | 0.5 |
| C15:0 pentadecanoic acid | 0.1 | N/A |
| C16:0 palmitic | 13.7 | 29.0 |
| C16:1 palmitoleic | 0.5 | 0.6 |
| C16:2 | 0.4 | N/A |
| C16:3 | 3.5 | N/A |
| C16:4 | 3.3 | N/A |
| C17:0 margaric | N/A | 0.2 |
| C17:1 margaroleic | N/A | 1.3 |
| C18:0 stearic | 0.7 | 2.1 |
| C18:1 oleic | 4.9 | 25.9 |
| C18:2 linoleic | 24.9 | 20.8 |
| C18:3 linolenic | 39.7 | 12.8 |
| C18:4 octadecatetraenoic | 5.8 | 1.4 |
| C20:0 arachidic | N/A | 0.6 |
| C20:1 gadoleic | 0.5 | 0.3 |
| C20:2 eicosadenoic | N/A | 1.2 |
| C20:3 eicosatrienoic gamma | N/A | 0.5 |
| C20:4 arachidonic | 0.9 | 1.4 |
| C20:5 eicosapentaenoic | 0.6 | 0.6 |
| C22:0 behenic | N/A | 0.4 |
| C24:0 lignoceric | 0.3 | 0.2 |
| C24:1 nervonic acid | 0.1 | 0.1 |
| ∑ SFAs | 15.0 | 33.2 |
| ∑ MUFAs | 6.0 | 28.1 |
| ∑ PUFAs | 79.1 | 38.7 |
| Total | 100.0 | 100.0 |
Figure 7Pathway of (3S-3′S)-astaxanthin biosynthesis in . Major carbon flux during the red stage of H. pluvialis cultivation is indicated with thick arrows, minor products are indicated with thin arrows. Major intermediates of biosynthesis are indicated in large fonts, minor intermediates in small fonts. Enzyme abbreviations are as follows: IPI, Isopentenyl pyrophosphate isomerase; HDR, 4-hydroxy-3-methylbut-2-enyl diphosphate reductase; GGPS, geranylgeranyl pyrophosphate synthase; PSY, phytoenesysthase; PDS, phytoenedesaturase; ZDS, ζ-carotene desaturase; LCY-b, lycopene β-cyclase; LCY-e, lycopene ε-cyclase; BKT, β-carotene ketolase; CrtR-b, β-carotene 3,3′-hydroxylase; Intermediates: Phytofluene, Neurosporene, γ-carotene, β-Cryptoxanthin, Adonixanthin, Echinenone, Adonirubin.
Effect of .
| Anti-oxidation | Rabbits | Thioredoxin reductase; Paraoxonase activity | Enhanced; No effect | Augusti et al., |
| Rats | Hepatoprotective and antioxidant activity | Improved | Ranga Rao et al., | |
| Rats | Antioxidant enzymes, catalase, superoxide dismutase, peroxidase, and lipid peroxidation in plasma and liver | Increased | Ranga Rao et al., | |
| Men (bilateral cataract) | Antioxidative effects through changes in superoxide scavenging activity, and hydroperoxides production in aqueous humor | Enhanced; Suppressed | Hashimoto et al., | |
| Eye function | 18 healthy men | Deep vision | Improved | Sawaki et al., |
| 10 healthy men | Eye function | Improved | Iwasaki and Tawara, | |
| 40 asthenopia patients | Eye accommodation power | Improved | Kenji et al., | |
| 49 healthy men | Uncorrected far visual acuity | Improved | Nakamura et al., | |
| 87 men (visual display terminal workers) | Eye accommodation amplitude (the adjustment in the lens of the eye that allows it to focus); | Improved; | Nagaki et al., | |
| Eye soreness, dryness, tiredness, and blurred vision | Reduced | Nagaki et al., | ||
| Skin | Healthy female or male | Skin wrinkle, corneocyte layer, epidermis, and dermis | Improved | Tominaga et al., |
| 46 healthy women | Skin elasticity and moisture | Improved | Seki et al., | |
| Immune response | 14 healthy women | Oxidative stress and inflammation markers; Immune response | Reduced; Improved | Park et al., |
| Inflammation | Rats | Gastrointestinal health | Improved | Nishikawa et al., |
| Gastric ulcer | Bacterial load Gastric inflamation | Reduced | Liu and Lee, | |
| Rats | Gastric ulcer markers | Reduced | Kamath et al., | |
| 44 patients with functional dyspepsia | Inflammatory markers; gastrointestinal discomfort | No effect; No effect | Andersen et al., | |
| Cardiovascular system | 20 adult men | Blood flow time | Improved | Miyawaki et al., |
| Men | Blood plasma levels | Reduced | Karppi et al., | |
| Muscle endurance | 16 non-trained men | Lactic acid accumulation after run | Reduced | Sawaki et al., |
| 19 non-trained men | Respiratory and sympathetic nervous system activities | Improved | Nagata et al., | |
| 20 non-trained men | Strength/explosiveness test; strength/endurance test | No effect; Improved | Lignell, | |
| 20 resistance-trained men | Markers of skeletal muscle injury | No effect | Bloomer et al., | |
| Cancer | Rats | Growth of colon cancer cells | Inhibited | Palozza et al., |
| Central nervous system | Healthy mice | Memory | Improved | Zhang et al., |
| 10 healthy men (50–69 years) | Response time and accuracy of several tasks | Improved | Satoh et al., | |
| Middle aged/elderly men and women | Cog Health battery scores (Nuropsychological memory test) | Improved | Katagiri et al., | |
| Male fertility | 20 sub-fertile men | Semen quality, pregnancy rate | Improved | Elgarem et al., |
| 30 sub-fertile men | Sperm velocity; oxidation markers; pregnancy rate | Improved; Reduced; Improved | Comhaire et al., | |
| 24 healthy men | Idiopathic infertility | Decreased | Andrisani et al., | |
| Metabolic Syndrome (MS) | Obese rats | Body weight; adipose tissue weight; MS markers | Reduced; Reduced; Improved | Ikeuchi et al., |
Summary of various methods of .
| Airlift column (30 L) | Indoor | Batch | Modified Bold's Basal medium | 0.03 | 0.01 | 2.7 | 0.44 | Harker et al., |
| Tubular /open pond (25,000 L) | Outdoor | – | Modified Bold's Basal Medium | 0.036–0.052 | N/A | 2.8–3.0 | N/A | Olaizola, |
| Tubular (50 L) | Indoor | Semi continuous | BG-11 medium | N/A | 0.05 | 3.6 | 7.2 | Torzillo et al., |
| Bubbling column (1.8) | Indoor | Batch | Basal inorganic culture medium | N/A | 0.6 | 0.8 | 5.6 | Del Río et al., |
| Airlift Tubular (55 L) | – | Inorganic medium free of acetate | N/A | 0.41 | 1.1 | 4.4 | López et al., | |
| Bubbling column (0.5 L) | Indoor | Batch | BG-11 medium | 0.5 | 0.21 | 4 | 11.5 | Aflalo et al., |
| Tubular (200 L) | Outdoor | Batch | BG-11 medium | 0.37 | 0.21 | 3.8 | 10.1 | Aflalo et al., |
| Bubbling column (1.8 L) | Indoor | Batch | Basal inorganic culture medium | N/A | 1.9 | 1.1 | 21 | Del Río et al., |
| Bubbling column (1 L) | Indoor | Batch | Standard inorganic medium | 0.36 | 0.14 | 3.6 | 12 | Ranjbar et al., |
| Tubular (1.8 L), outdoor, | Outdoor | Continuous | Standard inorganic medium | N/A | 0.7 | 1 | 8 | García-Malea et al., |
| Open pond | Indoor | Batch | BG-11 medium | N/A | 0.15 | 2.79 | 4.3 | Zhang et al., |
| Flat type (1 L) | Indoor | Fed batch | NIES-C medium | 0.33 | 0.44 | 4.8 | 14 | Kang et al., |
| Airlift column | Indoor | Batch | N/A | 0.14 | N/A | 3.3 | Choi et al., | |
| Bubbling column (6 L) | Indoor | Batch | NIES-C medium | N/A | 0.047 | N/A | 1.4 | Yoo et al., |
| Bubbling column (0.6 L) | Outdoor | Batch | BG-11 medium | N/A | 0.58 | 2.7 | 17.1 | Wang et al., |
| Bubbling column (0.6 L) | Outdoor | Batch | BG-11 medium | N/A | 0.30 | 3.8 | 16.0 | Wang et al., |
Obtained from one-step culture process.
Obtained from two-step culture process. Productivity value was calculated based on total time required by the “green stage” and “red stage” of cultivation.
Induction of astaxanthin was performed outdoors;
Obtained from a two-step process in which astaxanthin productivity was calculated based on time spent on the “red stage” only.
Detail medium composition can be found in relevant references.
Summary of astaxanthin extraction methods from .
| SC-CO2 at 20 MPa, 55°C and13% (w/w) ethanol for 120 min of extraction time. | 83% recovery | Reyes et al., |
| CO2 expanded ethanol (50% %w/w ethanol), 7 MPa, 45°C, 120 min of extraction time. | 124.2% recovery | Reyes et al., |
| SC- CO2 at at 20 MPa, 60°C, 2 ml of ethanol for 1 h of extraction time | 2.45 mg/g DW | Fujii, |
| SC- CO2, co-solvent 0.154–1% (v/v) ethanol, 7–34 MPa, 30–80°C, 0–100 min | 74% recovery | Pan et al., |
| SC- CO2, co-solvent 1.25–8.75% (v/v) ethanol, 30–50 MPa, 35–75°C, 210 min | 87.4% recovery | Wang et al., |
| SC- CO2, co-solvent 0–12% (v/v) vegetable oils, 30–50 MPa 50–80°C 300 min | 51% recovery | Krichnavaruk et al., |
| SC- CO2, co-solvent 30–50 MPa 40–80°C 60–240 min | 84% recovery | Thana et al., |
| SC- CO2, co-solvent, 1.67–7.5% (v/v) ethanol 20–55 MPa 40–80°C, 240 min | 80% recovery | Machmudah et al., |
| SC- CO2, co-solvent 0, 10% (v/v) ethanol 20–30 MPa, 40–60°C | 90% recovery | Nobre et al., |
| SC- CO2, co-solvent 0, 9.4% (w/w) ethanol, 30 MPa at 60°C | 97% recovery | Valderrama et al., |
| Cell germination (12 h), Ionic liquid (1-ethyl-3- methylimidazolium ethylsulfate) (24 h), | 32.5 pg/cell | Praveenkumar et al., |
| Direct extraction using liquefid dimethyl ether (DME) at 0.59 MPa and 25°C, without drying, cell disruption, or heating, | 1 (mg/g cell) | Boonnoun et al., |
| HCl:acetone (5:5), 70°C, 20 min | 19.8 mg/g cell | Dong et al., |
| Ultrasound in solvent (EtOH and EA), 16 min, 41°C, 40 kHz, 200 W, EtOH: ethyl acetate (20:1) | 28 (mg/g) | Zou et al., |
| Grinding three repetitions, pressurized hexane (10.3 Mpa) | 35 (mg/g cell) | Jaime et al., |
| Treating with enzymes (Viscozyme, Alcalase) at 50°C, 2 h | 2649 ± 359 μg/g cell | In, |
| Dodecane mixing 48 h, saponification with methanolic NaOH (0.02 M), sedimentation in darkness at 4°C, 12 h. | 85% efficiency | Kang and Sim, |
| Acid digestion, 2 N HCl, 70°C. Acetone extraction for 1 h | 87% efficiency | Sarada et al., |
| NaOH 30 min, Acetone (16 h) | 7 (mg/g cell) | Mendes-Pinto et al., |
| 40% (v/v) acetone for 2 min at 80°C, followed by lyophilization or treatment with specific lytic enzymes | 70% recovery | Kobayashi et al., |
SC, supercritical; EA, ethyl acetate.
Figure 8Scheme of two stage cultivation . Green stage of cultivation can be performed using either photoautotrophic cultivation (deep green section) or hetero/mixotrophic cultivation (pale green section) systems. Red stage cultivation (red section) takes place after green stage of H. pluvialis cultivation and is aimed to maximize astaxanthin content Recycling of waste is performed through anaerobic digestion process. Following annotations are used: solid arrows—subsequent steps; dashed arrows—optional steps; double lines—final products; double arrows—inputs; dotted lines—opportunities for recycling resources.
Leading commercial companies and their .
| Cyanotech Corporation ( | USA | BioAstin® | Astaxanthin extract packaged in soft gel, beadlets; dietary supplement |
| Naturose™ | Algae meal; pigmentation source for ornamental fish and animals | ||
| Mera Pharmaceutigals Inc. ( | USA | AstaFactor® | Astaxanthin packaged as soft gel; dietary supplement |
| Stazen Inc. ( | USA | Stazen® | Dietary supplement containing algae crushed and dried algae meal |
| Valensa International ( | USA | Zanthin® | Astaxanthin extract, soft gel, beadlets |
| AIgatechnologies Ltd. ( | Israel | AstaPure™ | Dry algal biomass, astaxanthin beadlets, and oleoresin |
| Fuji Chemical Industry Co. Ltd. (AstaReal Co Tld) ( | Japan, Sweden, USA | AstaREAL® | Astaxanthin oleoresin products, water dispersible, and soluble powders |
| BioReaI (Sweden) AB (subsidiary of Fuji Chemical) ( | Sweden | AstaXine® AstaCaroxe® | Dietary supplement containing algae crushed, and dried algae meal |
| AstaEquus® | Astaxanthin extract feed supplement for horses | ||
| Novaasta® | Astaxanthin extract feed supplement for animals | ||
| Britannia Health Products Ltd. ( | UK | Britaxan® | Astaxanthin complex with other carotenoids packaged as capsule- dietary supplement |
| Supreme Biotechnologies NZ Ltd. ( | New Zealand | AstaSupreme® | Algal biomass, Oleoresins, beadlets, and soft gels of Astaxanthin |
| Atacama Bio Natural ( | Chile | Supreme Asta Oil™ Supreme Asta powder™ | Oleoresin for food, nutraceutic, and cosmetic products, and powder for animal feed supplement |
| Jingzhou Natural Astaxanthin Inc. ( | China | NaturAsta™ | Dry algal biomass and astaxanthin soft gel |
| Kunming Biogenic Co. Ltd. ( | China | AstaBio® | Algal biomass, oleoresins, beadlets, and soft gels of Astaxanthin |
| Beijing Ginko Group (BGG) Biological Technology Co. Ltd. ( | China | AstaZine® | Astaxanthin oil, powder, and beadlets |
| Wefirst Biotechnology Co. Ltd. ( | China | AstaFirst™ | Dried algal powder, Astaxanthin oleoresin, and soft gel |
| Algaetech International SDN BHD ( | Malaysia | Astaxanthin Premia- | Algae biomass, oleoresin, and soft gel |
| Parry Nutraceuticals Ltd. (EID Parry) ( | India | Zanthin® | Astaxanthin oleoresins, beadlets, and soft gel |